Terms: = Ovarian cancer AND MYD88, Q99836, MYD88D, 4615 AND Prognosis
6 results:
1. [Expression of lnc-myd88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
[No Abstract] [Full Text] [Related]
2. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract] [Full Text] [Related]
3. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract] [Full Text] [Related]
4. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
[TBL] [Abstract] [Full Text] [Related]
5. The myd88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract] [Full Text] [Related]
6. Expression and significance of the TLR4/myd88 signaling pathway in ovarian epithelial cancers.
Kim KH; Jo MS; Suh DS; Yoon MS; Shin DH; Lee JH; Choi KU
World J Surg Oncol; 2012 Sep; 10():193. PubMed ID: 22985132
[TBL] [Abstract] [Full Text] [Related]